Noladin ether attenuates MPTP -induced motor deficit by abrogating pro-inflammatory cytokines and striatal neurochemical alterations in rats
Objective: The present study was designed to investigate the therapeutic potential of noladin ether- a putative endocannabinoid against MPTP-induced behavioral, biochemical and neurochemical alterations in…Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia
Objective: This is a retrospective biomarker study of an open-label clinical study to examine the safety and efficacy of lower doses (<50% of CML dose)…A single aerobic exercise session of treadmill increases BDNF levels in Parkinson’s disease patients
Objective: The aim of this study was to investigate the effect of a single session moderate-intensity treadmill exercise on serum levels brain-derived neurotrophic factor (BDNF)…Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).
Objective: Evaluation of the efficacy and safety of a slow release low dose combination of pramipexole (PPX) and rasagiline (RAS) (P2B001) in a prospective double-blind…Vitamin D and Clinical Phenotypes of Parkinson’s Disease
Objective: To explore the relationship of clinical phenotypes of Parkinson's disease (PD) with vitamin D levels in Veterans diagnosed with PD. Background: PD is a heterogeneous neurodegenerative…Istradefylline for daytime sleepiness and sleep disturbances in patients with Parkinson’s disease: an open-label, 3-month study
Objective: To evaluate the effect of istradefylline on daytime sleepiness and sleep disturbances as well as motor symptoms in patients with Parkinson’s disease (PD) in…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase
Objective: To determine the dose of APL-130277 required by each patient with Parkinson’s Disease (PD) to turn from OFF to Full ON. This dose is…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Prognosis and end-of-life status after emergency admissions in patients with Parkinson disease: a Japanese single center retrospective study
Objective: To investigate the status after the emergency admissions and to determine the cause and location of death in patients with Parkinson disease (PD). Background:…The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.